Pronota

NEW YORK (GenomeWeb) – Recently launched Biocartis-Pronota joint venture MyCartis is taking aim at the multi-omics space, looking to combine genomic, transcriptomic, and proteomic analyses for the development of research and clinical products.

Protein analysis firm Zephyrus Biosciences launched this week with Kelly Gardner as CEO, Josh Molho as chief technology officer, Brock Siegel as chief operating officer, Gary Zweiger as chief business development officer, Jenny Rooke as chief marketing officer, and Chris Hadsell as chief financia

NEW YORK (GenomeWeb) – Diagnostics firm Carmenta Bioscience has begun a multi-center clinical trial for its protein-based preeclampsia diagnostic with the aim of launching the test sometime next year.

Danaher said this week that it has appointed Thomas Joyce as president and CEO and member of the board of directors. He replaces Lawrence Culp, who will transition to a senior advisory role with the company.

NEW YORK (GenomeWeb) – Biocartis announced today that it has raised €64.5 million ($84 million) in a round of private financing.

NEW YORK (GenomeWeb) – Researchers at the University of Iowa have identified a potential peptide biomarker for preeclampsia.

A team led by scientists at the University of Manchester has identified a set of potential protein biomarkers for preeclampsia via a label-free selected-reaction monitoring mass spec workflow.

Combining metabolomics and proteomics, a consortium of academic and industry researchers has identified a signature that appears useful for predicting death in sepsis patients.

With positive data from two validation studies in hand, diagnostics firm Pronota is prepping its acute heart failure protein biomarker CD146 for a 2014 launch.

Maternal and fetal biomarker firm Carmenta Bioscience said last week it has acquired an option for a global, exclusive license from Stanford University for preeclampsia biomarkers that it plans to develop into a diagnostic panel for the condition.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.